NeuroKine Therapeutics (NKT), LLC, is a clinical stage drug development company focused on assets for serine/threonine protein kinase targets. Assets are from a technology platform that delivers de-risked candidates from basic research to early clinical development.
NKT employs lean biotech operational principles that use just-in-time business practices and academic collaborator interactions. The goal is asset de-risking and clinical evaluation.
USA and International patents cover matter and indications, providing a robust intellectual property foundation.
In the CNS disease domain, an emphasis is on the common yet neglected pathophysiology progression theme of synaptic dysfunction and neuroinflammation.